Helixgate https://validator.w3.org/feed/docs/rss2.html FDA Approves Pharming’s Joenja as First Treatment for Children with APDS in the U.S. BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi Electra aims for $342M IPO to power inflammatory drug’s push through phase 3 Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival Definium LSD drug goes 3 for 3 with another pivotal anxiety trial win AI automates 3D membrane mapping, matching manual results in a fraction of time STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests After a brief storm of political headwinds, mRNA is back with strong momentum Centric Compounding Issues Nationwide Recall of Glutathione, Myer’s Cocktail, and Tri-Immune Boost Due to Elevated Endotoxin Levels GSK prepares frontline FDA bid for Jideytro, its first lung cancer drug Merck, Gilead’s failed Trodelvy lung cancer trial shows better China results Increased deaths shadow AstraZeneca, Daiichi’s Enhertu first-line lung cancer data Akeso, Summit’s ivonescimab tops Keytruda in lung cancer survival, with strong data in PD-L1-high patients Tomato Gene SlXTH3 Opens the Door for Devastating Bacterial Wilt Pathogen Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance Psychedelic therapies ride wave of public favor into FDA hearing Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spree STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss Takeda’s Plump, GV’s Yeshwant announce retirement plans STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more STAT+: Pharma wins a battle over the cost of wastewater treatment in Europe STAT+: Up and down the ladder: The latest comings and goings Merck builds around Keytruda; prediction markets raise new risks Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing – 09/14/2026 The future of RAS inhibitors FDA delays approval decision for Exelixis’ tyrosine kinase inhibitor in colorectal cancer Singapore launches biotech-focused Boston hub to build on ‘centuries-old bond’ After FDA nod for novel Cabometyx formulation, analysts predict limited threat to Exelixis Fierce Pharma Asia—Takeda’s R&D leadership change; Daiichi’s $1.3B court win; New Samsung Bio contract CDMO Argonaut sheds life sciences, diagnostics division for undisclosed sum In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy ABEC to expand global manufacturing network with new Wilson facility Exegenesis Bio and Modalis sign research deal for Duchenne therapy FDA approves first treatment for children aged 4-11 years with APDS, a rare genetic disorder of the immune system Eco-NAMs Webinar Series | QSARs to Predict Aquatic Toxicity – 09/17/2026 Advancing Generic Drug Development: Modernizing Bioequivalence Approaches for Topical & Transdermal Products – 09/10/2026 FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy Notable Approvals | Drugs Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer NLS Days 2026: what’s dealmaking like in the Nordics? Selective oestrogen receptor degrader class grows with new cancer approval Samsung Biologics inks $262M manufacturing deal with European pharma company Encoded raises $275m for Dravet therapy and other financings Home